Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer  

作　　者：Miguel J Sotelo Jose Luis García Cesar Torres-Mattos Héctor Milián Carlos Carracedo María Angeles González-Ruiz Xabier Mielgo-Rubio Juan Carlos Trujillo-Reyes Felipe Couñago 

机构地区：[1]Department of Medical Oncology,Hospital María Auxiliadora,Department of Medical Oncology,Centro Oncológico Aliada,Oncological Research Unit,Clínica San Gabriel,Lima 15801,Peru [2]Department of Thoracic Surgery,Hospital Universitario La Princesa,Department of Thoracic Surgery,MD Anderson Cancer Center,Department of Thoracic Surgery,Hospital HM,Madrid 28006,Spain [3]Department of Medical Oncology,Hospital Nacional Guillermo Almenara,Oncological Research Unit,Clínica San Gabriel,Lima 15033,Peru [4]Department of Thoracic Surgery,Hospital Universitario La Princesa,Madrid 28006,Spain [5]Department of Medical Oncology,Centro Oncológico Aliada,Lima 15036,Peru [6]Department of Radiation Oncology,Hospital Universitario Virgen Macarena,Sevilla 41009,Spain [7]Department of Oncology,Hospital Universitario Fundación Alcorcón,Alcorcón 28922,Madrid,Spain [8]Department of Thoracic Surgery,Hospital de la Santa Creu i Sant Pau,Barcelona 08041,Spain [9]Department of Radiation Oncology,Hospital Universitario Quirónsalud Madrid,Hospital La Luz,Universidad Europea de Madrid,Madrid 28223,Spain

出　　处：《World Journal of Clinical Oncology》2021年第10期912-925,共14页世界临床肿瘤学杂志（英文版）

摘　　要：Patients with early-stage non-small-cell lung cancer(NSCLC)are candidates for curative surgery;however,despite multiple advances in lung cancer management,recurrence rates remain high.Adjuvant chemotherapy has been demonstrated to significantly prolong overall survival(OS),but this benefit is modest and there is an urgent need for effective new therapies to provide a cure for more patients.The high efficacy of tyrosine kinase inhibitors(TKIs)against epidermal growth factor receptor-mutated(EGFR)in patients with advanced EGFR-mutated NSCLC has led to the evaluation of these agents in early stages of the disease.Multiple clinical trials have evaluated the safety and efficacy of EGFR TKIs as an adjuvant treatment,in patients with resected EGFR-mutated NSCLC,and shown that they significantly prolong disease-free survival(DFS),but this benefit does not translate to OS.Recently,an interim analysis of the ADAURA trial demonstrated that,surprisingly,osimertinib improved DFS.This led to the study being stopped early,leaving many unanswered questions about its potential effect on OS and its incorporation as a standard adjuvant treatment in this patient subgroup.These targeted agents are also being evaluated in locally-advanced disease,with promising results,although prospective studies with larger sample sizes are needed to confirm these results.In this article,we review the most relevant studies on the role of EGFR TKIs in the management of early-stage EGFR-mutated NSCLC.

关 键 词：Non-small-cell lung cancer Early stage Epidermal growth factor receptormutated Epidermal growth factor receptor-mutated-tyrosine kinase inhibitor ADJUVANT NEOADJUVANT 

分 类 号：R734.2[医药卫生—肿瘤]